Evidence
The Science Library
The peer-reviewed research behind every protocol in Beyond The Scale. Start with the anchor studies, then go as deep as you want.
Anchor studies
A curated set of the landmark studies behind the book's core claims, in plain language.
The medication does what it promises
Weekly semaglutide produced about 15 percent average body weight loss over 68 weeks.
The trial that moved obesity medicine from single digits to double digits, and the reason the modern GLP-1 era exists.
Weekly tirzepatide produced up to about 21 percent average body weight loss over 72 weeks.
The dual-hormone agent that raised the ceiling again and set the benchmark the next generation is measured against.
In people with obesity and established heart disease but without diabetes, semaglutide reduced major cardiovascular events by about 20 percent.
Evidence that the benefit reaches past the scale, and the clearest case that these drugs are more than cosmetic.
What the scale does not show
A meaningful share of the weight lost during therapy is lean mass rather than fat when protein and resistance training are inadequate.
Why the scale alone hides the cost, and why body composition is the number that actually matters.
Real-world users of GLP-1 medications show a measurable rise in micronutrient deficiencies.
Eating less does not only mean fewer calories. It means fewer of the vitamins and minerals your body runs on.
What actually protects you
Adding resistance training during GLP-1 weight loss preserved lean body mass that was otherwise lost.
The most actionable finding in the book. The muscle is protectable, but only if you do the work.
Adequate protein meaningfully increases the muscle and strength gained from resistance training.
The dosing logic behind protecting lean mass, anchored to the tissue you are trying to keep.
What happens if you stop
After stopping semaglutide, participants regained about two-thirds of the weight they had lost within a year.
The exit is not neutral. Stopping without a plan tends to undo the result.
Modeling of the regain curve shows weight returns along a predictable nonlinear path after discontinuation.
Regain is not random. It follows a shape, which means it can be anticipated and planned for.
The experience itself
Food noise, the intrusive and persistent preoccupation with food, was formally defined and measured.
Putting a name and a metric to the experience patients describe, and to what these drugs quiet.
The complete reference list
The full peer-reviewed reference list behind Beyond The Scale, spanning endocrinology, body composition, mitochondrial function, methylation, and more.
Download the full reference list (PDF)Keep going
Read
Get the book
Beyond The Scale, the complete clinical architecture for safer, smarter GLP-1 therapy.
Explore the bookAssess
Take the GLP-1 quiz
Seven questions mapped to the 8 Systems Framework. See which systems to monitor first.
Start the quizTest
Learn about GPS testing
Balance Protocol GPS, the precision testing platform behind Dr. Beck's protocols.
Visit Balance Protocol GPS